Free Trial

10x Genomics (TXG) Stock Forecast & Price Target

$18.11
+1.41 (+8.44%)
(As of 07/22/2024 ET)

10x Genomics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Based on 14 Wall Street analysts who have issued ratings for 10x Genomics in the last 12 months, the stock has a consensus rating of "Hold." Out of the 14 analysts, 1 has given a sell rating, 7 have given a hold rating, and 6 have given a buy rating for TXG.

Consensus Price Target

$37.57
107.46% Upside
High Forecast$75.00
Average Forecast$37.57
Low Forecast$16.00

According to the 14 analysts' twelve-month price targets for 10x Genomics, the average price target is $37.57. The highest price target for TXG is $75.00, while the lowest price target for TXG is $16.00. The average price target represents a forecasted upside of 107.46% from the current price of $18.11.

TypeCurrent Forecast
7/24/23 to 7/23/24
1 Month Ago
6/24/23 to 6/23/24
3 Months Ago
4/25/23 to 4/24/24
1 Year Ago
7/24/22 to 7/24/23
Consensus Rating
Hold
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
6 Buy rating(s)
8 Buy rating(s)
8 Buy rating(s)
6 Buy rating(s)
Hold
7 Hold rating(s)
4 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$37.57$46.62$60.22$56.50
Forecasted Upside107.46% Upside29.42% Upside28.32% Upside25.34% Upside
Get 10x Genomics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for TXG and its competitors with MarketBeat's FREE daily newsletter.

TXG Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

TXG Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

10x Genomics Stock vs. The Competition

Type10x GenomicsMedical CompaniesS&P 500
Consensus Rating Score
2.36
2.72
2.51
Consensus RatingHoldModerate BuyModerate Buy
Predicted Upside107.46% Upside3,020.72% Upside9.23% Upside
News Sentiment RatingNeutral News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
7/22/2024Jefferies Financial Group
2 of 5 stars
 UpgradeHold ➝ Buy$24.00 ➝ $24.00+43.71%
7/18/2024Bank of America
4 of 5 stars
 Lower TargetNeutral ➝ Neutral$36.00 ➝ $25.00+26.01%
7/18/2024JPMorgan Chase & Co.
3 of 5 stars
 DowngradeOverweight ➝ Neutral$40.00 ➝ $20.00+0.81%
7/16/2024Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$53.00 ➝ $25.00+44.34%
7/10/2024Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold$55.00 ➝ $25.00+36.99%
7/9/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetSell ➝ Sell$26.00 ➝ $16.00-10.56%
6/28/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$36.00 ➝ $24.00+21.33%
6/27/2024Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
D. Schenkel
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Peer Perform
6/25/2024Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
S. Nambi
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral
5/1/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral ➝ Neutral$52.00 ➝ $30.00+11.69%
5/1/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold$57.00 ➝ $32.00+9.29%
4/29/2024Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$65.00 ➝ $50.00+74.46%
8/7/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight ➝ Overweight$65.00+18.20%
8/4/2023Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$65.00 ➝ $75.00+28.23%
3/30/2023Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOverweight$65.00+24.88%
2/16/2023Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$52.00 ➝ $57.00+23.19%
8/15/2022Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$55.00+15.59%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 03:34 AM ET.

TXG Forecast - Frequently Asked Questions

What is 10x Genomics' forecast for 2024?

According to the research reports of 14 Wall Street equities research analysts, the average twelve-month stock price forecast for 10x Genomics is $37.57, with a high forecast of $75.00 and a low forecast of $16.00.

Should I buy or sell 10x Genomics stock right now?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for 10x Genomics in the last twelve months. There is currently 1 sell rating, 7 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" TXG shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TXG, but not buy additional shares or sell existing shares.

Does 10x Genomics's stock price have much upside?

According to analysts, 10x Genomics's stock has a predicted upside of 29.28% based on their 12-month stock forecasts.

Has 10x Genomics been upgraded or downgraded by Wall Street analysts recently?

Over the previous 90 days, 10x Genomics's stock had 3 downgrades and 1 upgrade by analysts.

What analysts cover 10x Genomics?
Do Wall Street analysts like 10x Genomics more than its competitors?

Analysts like 10x Genomics less than other "medical" companies. The consensus rating for 10x Genomics is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how TXG compares to other companies.


This page (NASDAQ:TXG) was last updated on 7/23/2024 by MarketBeat.com Staff

From Our Partners